A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
Public ClinicalTrials.gov record NCT02545868. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).
Study identification
- NCT ID
- NCT02545868
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Interventions
- 23-PPV Biological
- 13-PCV Booster Biological
- Influenza Vaccine Biological
- KLH Biological
- OCR Drug
- TT Vaccine Biological
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2015 (Actual)
- Primary completion
- Feb 14, 2017 (Actual)
- Completion
- Sep 21, 2021 (Actual)
- Last update posted
- Mar 26, 2024
2015 – 2021
United States locations
- U.S. sites
- 20
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| North Central Neurology Associates | Cullman | Alabama | 35058 | — |
| Territory Neurology and Research Institute | Tucson | Arizona | 85704 | — |
| Fullerton Neurology and Headache Center | Fullerton | California | 92835 | — |
| Scripps Clinic | La Jolla | California | 92037 | — |
| University of Miami School of Medicine; Dept. of Neurology Movement Disorder Center | Miami | Florida | 33136 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| Michigan Institute for Neurological Disorders | Farmington Hills | Michigan | 48334 | — |
| The Minneapolis Clinic of Neurology | Golden Valley | Minnesota | 55422 | — |
| Mercy Hospital St. Louis / Mercy Clinic Neurology | Chesterfield | Missouri | 63017 | — |
| Cleveland Clinic Lou Ruvo; Center for Brain Research | Las Vegas | Nevada | 89106 | — |
| University of New Mexico | Albuquerque | New Mexico | 87131 | — |
| Staten Island Univ Hospital | Staten Island | New York | 10306 | — |
| Neurology Associates PA | Hickory | North Carolina | 28602 | — |
| Ohio Health Research Institute Grant Medical Center | Columbus | Ohio | 43214 | — |
| MDH Research LLC | Westerville | Ohio | 43082 | — |
| Abington Neurological Associates | Abington | Pennsylvania | 19001 | — |
| Neurology Clinic PC | Cordova | Tennessee | 38018 | — |
| Central Texas Neurology Consultants | Round Rock | Texas | 78681 | — |
| Rocky Mountain MS Clinic | Salt Lake City | Utah | 84103 | — |
| Swedish Medical Center | Seattle | Washington | 98104-1360 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02545868, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2024 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02545868 live on ClinicalTrials.gov.